Announcement of the National Medical Products Administration, the Ministry of Public Security, and the National Health Commission, on the Inclusion of Varieties including Oxycodone-containing Medicines as Psychotropic Drugs

2019-08-13

Provisions for In-vitro Diagnostic Reagent Registration

2019-07-25

The Provisions for In-vitro Diagnostic Reagent Registration, adopted at the executive meeting of China Food and Drug Administration on June 27, 2014, is hereby promulgated and shall be effective as of October 1, 2014.

Provisions for Supervision of Drug Distribution

2019-07-25

The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.

Provisions for Drug Registration

2019-07-25

The Provisions are formulated for the purposes of ensuring the safety, efficacy and quality of drugs and regulating drug registration in accordance with the Drug Administration Law of the People's Republic of China, Administrative Permission Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China.

Provisions for Drug Insert Sheets and Labels

2019-07-25

The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and Drug Administration on March 10, 2006, is hereby promulgated and shall go into effect as of June 1, 2006.

Good Manufacturing Practice for Drugs (2010 Revision)

2019-07-25

The Good Manufacturing Practice for Drugs (2010 Revision), adopted at the executive meeting of the Ministry of Health on October 19, 2010, is hereby promulgated and shall go into effect as of March 1, 2011.